TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities March 11, 2022
Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial February 14, 2022
